Acurx Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
ACXP$1.06+12.1%Stored close · as of Nov 6, 2026
Contents
Statements of Changes in Shareholders’ Equity
| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | | |
| · · Common Stock · · · · · · · · · | ||||||||||||||
| | | | | | | | | Additional | | | | | | Total |
| · · · Paid-In · Accumulated · Shareholders’ | ||||||||||||||
| | | Shares | | | Amount | | | Capital | | | Deficit | | | Equity |
| Balance at January 1, 2022 | 10,215,792 | $10,216 | $38,948,334 | $(26,548,309) | $12,410,241 | |||||||||
| Share-Based Compensation | | — | | — | | 2,871,681 | | — | | | 2,871,681 | |||
| Share-Based Payments to Vendors | | 114,889 | | 115 | | 430,565 | | — | | 430,680 | ||||
| Issuance of shares of common stock and pre-funded warrants in registered direct offering, net of $529,805 cash issuance costs | | 1,159,211 | | | 1,159 | | | 3,694,023 | | — | | 3,695,182 | ||
| Cashless Warrant Exercise | | 6,948 | | | 7 | | | (7) | | — | | — | ||
| Pre-funded Warrant Exercise | | 130,769 | | | 131 | | | (118) | | — | | 13 | ||
| Net Loss | — | | — | | — | | (12,092,776) | | | (12,092,776) | ||||
| Balance at December 31, 2022 | 11,627,609 | | 11,628 | | 45,944,478 | | (38,641,085) | | 7,315,021 | |||||
| Share-Based Compensation | | — | | — | | 3,206,527 | | — | | 3,206,527 | ||||
| Share-Based Payments to Vendors | | 140,186 | | 140 | | 559,443 | | — | | 559,583 | ||||
| Issuance of shares of common stock and pre-funded warrants in registered direct offering, net of $456,314 cash issuance costs | | 601,851 | | | 602 | | | 3,543,010 | | — | | 3,543,612 | ||
| Issuance of shares of common stock in At-the-Market sales agreement, net of $222,161 cash issuance costs | | 680,252 | | | 680 | | | 2,399,958 | | | — | | | 2,400,638 |
| Warrant Exercise | | 682,769 | | | 683 | | | 2,218,316 | | | — | | | 2,218,999 |
| Cashless Warrant Exercise | | 4,080 | | | 4 | | | (4) | | — | | — | ||
| Pre-funded Warrant Exercise | | 731,482 | | | 731 | | | (658) | | — | | 73 | ||
| Net Loss | — | | — | | — | | (14,577,768) | | (14,577,768) | |||||
| Balance at December 31, 2023 | 14,468,229 | | $14,468 | | $57,871,070 | | $(53,218,853) | | $4,666,685 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.